25 results about "Staphylococcal infections" patented technology

Provided herein are methods and systems for use in determining risk of a Staphylococcus infection, predicting efficacy of a Staphylococcus vaccine, and prognosing clinical outcomes on a subject exposed to Staphylococcus. Methods of treating subject identified as having or at risk of a Staphylococcus infection are further provided.

The invention belongs to the technical field of biological medicine, and particularly relates to a PDHC mutant, an immunogenic fragment and application, the PDHC mutant has amino acid mutation at at least one of the 214th site, the 274th site or the 294th site of the amino acid sequence shown in SEQ ID NO: 1, and the PDHC mutant is used for preventing or treating staphylococcus aureus (SA) infection and is an mRNA vaccine for preventing or treating staphylococcus aureus (SA) infection. The stability and immunogenicity of the staphylococcus aureus PDHC antigen are greatly improved, efficient targeted delivery of the antigen is achieved, and the immune effect of the vaccine is remarkably improved.

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

The invention discloses a manganese-based nano-enzyme preparation method, a manganese-based nano-enzyme product and an application of the manganese-based nano-enzyme product in antibiosis, and belongs to the technical field of nano-enzymes and biomedicine nanotechnology. According to the preparation method, KMnO4 and C18H34O2 are used as raw materials, and the manganese-based nano-enzyme is prepared through a water phase method. The nano-enzyme shows good application prospects in removing bacterial biofilms, inhibiting bacteria from forming biofilms and treating wound infection models. Animal experiments show that the hydrogel has excellent biocompatibility, is free of toxic accumulation, and can effectively treat mouse wound staphylococcus aureus infection and promote wound healing.

The invention discloses an antigen protein as well as a preparation method and application thereof. The antigen protein comprises a soluble catalytic domain of the membrane protein LCP or a variant thereof. The antigen protein can be used for preventing and treating staphylococcus aureus infection, especially drug-resistant bacteria infection, and clinical related infectious diseases caused by the staphylococcus aureus infection, so that more stable broad-spectrum protection on staphylococcus aureus infection, especially drug-resistant staphylococcus aureus, is realized.

The application provides a staphylococcus aureus toxin LukG antigen epitope peptide, comprising a polypeptide with an amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 40 or SEQ ID NO: 42, and the application also provides application of the antigen epitope peptide in preparation of a staphylococcus aureus infection diagnostic, preventive or therapeutic product. The application determines a staphylococcus aureus toxin LukG antibody dominant epitope peptide through screening, and the staphylococcus aureus toxin LukG antibody dominant epitope peptide has strong immunogenicity and can be used for staphylococcus aureus infection diagnosis, prevention or treatment.

The present application relates to the application of Staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treating Staphylococcus aureus infection. Specifically, it relates to the application of Staphylococcus aureus toxin protein related gene SA1833 and / or SA1832 as a target in the preparation of a drug for treating drug-resistant Staphylococcus aureus infection, preferably, the drug resistance is preferably methicillin resistance. With SA1833 and / or SA1832 as a target, the clinical treatment of repeated and persistent infection caused by methicillin-resistant Staphylococcus aureus retention has a significant effect. It provides a new target for the development of drugs for treating repeated infection caused by clinical MRSA strains, provides more choices for the treatment of Staphylococcus aureus, and has a wide application prospect.

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and / or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

The application provides a recombinant chicken antibacterial peptide against drug-resistant Staphylococcus aureus and belongs to the field of veterinary technology. The recombinant chicken antibacterial peptide is expressed by genetically engineering recombinant Escherichia coli. Three active regions of natural chicken antibacterial peptides are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to the outer membrane protein of Staphylococcus aureus. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to drug-resistant Staphylococcus aureus is significantly lower than that of the three natural chicken antibacterial peptides, and the minimum inhibitory concentration of 8 μg / mL can completely inhibit the formation of a biological membrane of a drug-resistant Staphylococcus aureus USA300 strain. The recombinant chicken antibacterial peptide has good antibacterial effect on different drug-resistant Staphylococcus aureus isolated from a chicken farm, and can effectively solve the problem of drug-resistant Staphylococcus aureus infection in the chicken farm.

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and / or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

The invention discloses an application of a compound 3546847 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 3546847 can neutralize the toxicity of staphylococcus aureus hemolysin, and has a protective effect on MRSA staphylococcus aureus USA300 infected mice. The compound 3546847 can be applied to preparation of anti-staphylococcus aureus hemolysin medicines and medicines for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 3546847 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 3546847 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so as to relieve inflammatory injury.

This disclosure provides a method reducing the number of Staphylococcus aureus bacterial cells in a subject and a method of treating or preventing diseases or disorders caused by S. aureus. This disclosure also provides a method of diagnosis or prognosis of a disease or disorder caused by S. aureus.

The invention provides an anti-staphylococcus aureus specific antibody as well as a nucleic acid coding sequence and application thereof. The anti-staphylococcus aureus specific antibody provided by the invention achieves the effects of treating staphylococcus aureus infection and enhancing immune cells against staphylococcus aureus through a plurality of efficacy experiments.

The present invention relates to the field of medicine, in particular to the field of treatment of pathologies associated with Staphylococcus infections. The present invention relates to novel endolysin polypeptides that specifically target bacterial Staphylococcus cells. The present invention further relates to said endolysin polypeptides for medical use, preferably for treating individuals suffering from pathologies associated with Staphylococcus infections.

The present invention relates to a novel immunogenic composition, fusion protein, recombinant vaccine, and molecular architecture design and application for the prevention and treatment of Staphylococcus aureus infection. The present invention provides a novel fusion molecular architecture comprising fusion proteins encoded by three genes, Tuf, SpxA, and Hu genes, or comprising fusion proteins encoded by two genes, Hla_H35L and EsxB genes. The present invention has discovered that the novel fusion molecule has good immunogenicity and can provide effective immunoprotective effects, and can clear Staphylococcus aureus colonization in some individuals, which can be used for the development of nucleic acid vaccines or subunit vaccines. The novel molecular architecture of the present invention can effectively enhance the expression level of fusion proteins, thereby further improving the immunoprotective effects. The present invention can be applied to the production and development of immune drugs for Staphylococcus aureus nucleic acid vaccines in humans and animals, and has broad application prospects.

The current disclosure provides novel compositions for treating bacterial infections. Accordingly, aspects of the disclosure relate to an engineered antibody comprising: LCDR1, LCDR2, and LCDR3 of the light chain variable region of the 3F6 antibody and HCDR1, HCDR2, and HCDR3 of the heavy chain variable region of the 3F6 antibody. Also provided are compositions comprising the antibodies and nucleic acids encoding either the heavy chain or light chain (or both) of the antibodies. Other aspects relate to host cells comprising the antibodies and / or nucleic acids of the disclosure. Further aspects relate to a method of preventing or treating staphylococcal infection comprising the step of administering the antibody of the disclosure to a subject in need thereof. Yet further aspects relate to a method of making the antibody comprising expressing the nucleic acid(s) of the disclosure in a cell and isolating the expressed protein.

The invention provides a medical application of resortanol in preparation of a staphylococcus aureus inhibitor, belongs to the technical field of biological medicines, and provides a novel medical application of resortanol, which can significantly inhibit growth of methicillin-resistant staphylococcus aureus and formation of a biofilm, and can inhibit the growth of methicillin-resistant staphylococcus aureus. The survival rate of methicillin-resistant staphylococcus aureus infection greater wax moth larvae can be obviously improved; the compound can be used for preparing a staphylococcus aureus inhibitor, a new candidate drug is provided for clinical treatment of multi-drug-resistant staphylococcus aureus infection, and the resorpterol and appropriate pharmaceutic adjuvants can be prepared into an injection for preparing drugs for systemic infection caused by methicillin-resistant staphylococcus aureus.

The invention discloses an application of a compound L604-0819 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound L604-0819 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protective effect on MRSA staphylococcus aureus USA300 infected mice, and has the application of preparing a staphylococcus aureus hemolysin resisting medicine and a staphylococcus aureus infection preventing or treating medicine. According to the invention, the new medicinal value of the compound L604-0819 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound L604-0819 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.

The invention discloses an antibody aiming at staphylococcus aureus IsdB and application of the antibody. The antibody comprises heavy chain variable regions and light chain variable regions, amino acid sequences of the heavy chain variable regions CDR1, CDR2 and CDR3 are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and amino acid sequences of the light chain variable regions CDR1, CDR2 and CDR3 are respectively shown as SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11. In addition, the invention also discloses a product for detecting the staphylococcus aureus IsdB and application of the antibody in preparation of medicines for diagnosing, preventing and / or treating staphylococcus aureus infection related diseases. The invention provides a new thought for the detection of staphylococcus aureus IsdB and the treatment of related diseases, and has a wide application prospect.

The present invention belongs to the fields of infectious microbial diseases and medicines. Provided is the use of compound 5928-0054 in the preparation of a drug against Staphylococcus aureus hemolysin. It is found that compound 5928-0054 can neutralize the toxicity of Staphylococcus aureus hemolysin, exhibits a protective effect on mice infected with MRSA Staphylococcus aureus USA300, and can be used in the preparation of a drug against Staphylococcus aureus hemolysin and a drug for preventing or treating Staphylococcus aureus infections. Compound 5928-0054 is found to have a new pharmaceutical value, i.e. providing a new drug for the prevention and treatment of Staphylococcus aureus infections. Compound 5928-0054 can neutralize hemolysin, the major virulence factor of Staphylococcus aureus, thereby alleviating inflammatory injuries.

The present application belongs to the technical field of biological medicine, and particularly relates to an antibacterial peptide with the functions of targeting Staphylococcus aureus and inhibiting quorum sensing signal and antibacterial effect. The present application first synthesizes a non-sulfur lactone AIP-III variant CP7 with the functions of targeting and inhibiting QS signal pathway in Staphylococcus aureus cells, and synthesizes an FP13-2 antibacterial peptide with broad-spectrum antibacterial activity, and then successfully synthesizes a composite peptide containing the CP7 domain and the FP13-2 domain. The composite peptide of the present application can target and kill Staphylococcus aureus, and is also effective for methicillin-resistant Staphylococcus aureus. The composite peptide of the present application has high antibacterial activity in vivo and in vitro, and has moderate toxicity. In addition, the mechanism of the composite peptide is different from that of traditional antibiotics, and the composite peptide is not prone to drug resistance, thereby providing certain guidance value for treating Staphylococcus aureus infection and drug-resistant bacteria.

The application discloses a bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9, and the amino acid sequence of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 is KLVVHRARRIQFFLSQNFH, and the molecular weight of the antibacterial peptide is 2396.831 Dalton. The antibacterial peptide has obvious inhibiting effect on Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus, and can be used for preparing medicines for preventing or inhibiting Vibrio parahaemolyticus, Staphylococcus aureus and Staphylococcus haemolyticus infection, food preservatives or feed additives.